Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares were down 3.1% during mid-day trading on Thursday . The stock traded as low as $9.45 and last traded at $9.45. Approximately 1,148 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 2,762 shares. The stock had previously closed at $9.75.
Clinuvel Pharmaceuticals Price Performance
The company’s 50-day moving average is $9.65 and its 200-day moving average is $9.86.
Clinuvel Pharmaceuticals Increases Dividend
The business also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a dividend of $0.0299 per share. The ex-dividend date of this dividend was Monday, September 9th. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Read More
- Five stocks we like better than Clinuvel Pharmaceuticals
- What Are Dividend Contenders? Investing in Dividend Contenders
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What Are Dividend Challengers?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-tbk-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
